BR112014010868B1 - composto isolado de fórmula (i), composição farmacêutica ou nutracêutica, método de produção de um composto de fórmula (i) e uso de uma quantidade terapeuticamente efetiva de um composto de fórmula (i) - Google Patents

composto isolado de fórmula (i), composição farmacêutica ou nutracêutica, método de produção de um composto de fórmula (i) e uso de uma quantidade terapeuticamente efetiva de um composto de fórmula (i) Download PDF

Info

Publication number
BR112014010868B1
BR112014010868B1 BR112014010868-4A BR112014010868A BR112014010868B1 BR 112014010868 B1 BR112014010868 B1 BR 112014010868B1 BR 112014010868 A BR112014010868 A BR 112014010868A BR 112014010868 B1 BR112014010868 B1 BR 112014010868B1
Authority
BR
Brazil
Prior art keywords
compound
formula
hydrogen
hydroxyl
double bond
Prior art date
Application number
BR112014010868-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014010868A8 (pt
BR112014010868A2 (pt
Inventor
Shibnath Ghosal
Muruganandam Veeraragavan
Sanyasi R. Kalidindi
Original Assignee
Natreon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natreon, Inc. filed Critical Natreon, Inc.
Publication of BR112014010868A2 publication Critical patent/BR112014010868A2/pt
Publication of BR112014010868A8 publication Critical patent/BR112014010868A8/pt
Publication of BR112014010868B1 publication Critical patent/BR112014010868B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112014010868-4A 2011-11-07 2012-11-06 composto isolado de fórmula (i), composição farmacêutica ou nutracêutica, método de produção de um composto de fórmula (i) e uso de uma quantidade terapeuticamente efetiva de um composto de fórmula (i) BR112014010868B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556603P 2011-11-07 2011-11-07
US61/556,603 2011-11-07
US13/669,207 2012-11-05
US13/669,207 US9084800B2 (en) 2011-11-07 2012-11-05 Indolealkylamino-withasteroid conjugates and method of use
PCT/US2012/063727 WO2013070619A1 (en) 2011-11-07 2012-11-06 Indolealkylamino-withasteroid conjugates and method of use

Publications (3)

Publication Number Publication Date
BR112014010868A2 BR112014010868A2 (pt) 2017-06-13
BR112014010868A8 BR112014010868A8 (pt) 2020-04-22
BR112014010868B1 true BR112014010868B1 (pt) 2021-07-06

Family

ID=48223848

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010868-4A BR112014010868B1 (pt) 2011-11-07 2012-11-06 composto isolado de fórmula (i), composição farmacêutica ou nutracêutica, método de produção de um composto de fórmula (i) e uso de uma quantidade terapeuticamente efetiva de um composto de fórmula (i)

Country Status (7)

Country Link
US (2) US9084800B2 (enExample)
EP (1) EP2776462B1 (enExample)
JP (1) JP6144688B2 (enExample)
CN (1) CN103917558B (enExample)
BR (1) BR112014010868B1 (enExample)
CA (1) CA2854631C (enExample)
WO (1) WO2013070619A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503990A (zh) * 2015-12-29 2016-04-20 吴金凤 一种新的睡加内酯类化合物及其制备方法和医药用途
WO2018156202A1 (en) 2017-02-27 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-psychotic composition and treatment methods
CN119631978B (zh) * 2024-12-18 2026-06-30 云南洛宇生物科技有限公司 一种树鼩阿尔兹海默症造模方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494698A1 (fr) * 1980-11-21 1982-05-28 Roussel Uclaf Nouveaux derives steroides 3-amino substitues, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6153198A (en) * 1999-07-13 2000-11-28 Natreon Inc. Withania somnifera composition
EP1421198A4 (en) * 2001-06-26 2006-08-30 New York State Office Of Menta SCREENING METHODS WITH HIGH CYCLE-BASED FLOW
US6713092B1 (en) * 2002-12-03 2004-03-30 Natreon Inc. Withania Somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
US20050266100A1 (en) * 2004-03-30 2005-12-01 Council Of Scientific And Industrial Research Rafi Marg Process isolation of withaferin-A from plant materials and products therefrom
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
JP5704484B2 (ja) 2008-03-06 2015-04-22 独立行政法人産業技術総合研究所 アシュワガンダ葉水抽出物を有効成分として含む組成物及びその製造方法
WO2010030395A2 (en) 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof

Also Published As

Publication number Publication date
BR112014010868A8 (pt) 2020-04-22
US9084800B2 (en) 2015-07-21
US20150320771A1 (en) 2015-11-12
US20130115316A1 (en) 2013-05-09
EP2776462A4 (en) 2015-04-08
JP6144688B2 (ja) 2017-06-07
WO2013070619A1 (en) 2013-05-16
CA2854631A1 (en) 2013-05-16
CA2854631C (en) 2018-12-11
EP2776462B1 (en) 2018-01-10
JP2015501787A (ja) 2015-01-19
CN103917558A (zh) 2014-07-09
WO2013070619A8 (en) 2014-05-08
CN103917558B (zh) 2017-04-12
US10449206B2 (en) 2019-10-22
BR112014010868A2 (pt) 2017-06-13
EP2776462A1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
Zhu et al. 4-Hydroxybenzyl alcohol derivatives and their sedative–hypnotic activities
Atta et al. The antinociceptive effect of some Egyptian medicinal plant extracts
Kim et al. Neuroprotective phenylpropanoid esters of rhamnose isolated from roots of Scrophularia buergeriana
AU2010275476B2 (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
Ajayi et al. Acetylcholinesterase inhibitor from Anthocleista vogelii leaf extracts
de Campos et al. Antinociceptive properties of the hydroalcoholic extract and preliminary study of a xanthone isolated from Polygala cyparissias (Polygalaceae)
Ramalingam et al. Free radical scavenging and antiepileptic activity of Leucas lanata
US10449206B2 (en) Indolealkylamino-withasteroid conjugates and method of use
KR100711028B1 (ko) 향나무 추출물 또는 세드롤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
BR112013028221B1 (pt) Composição para tratamento de distúrbios autoimunes, seu uso e seu método de preparação
Kingsley et al. Anti-diabetic activity of active fractions of Stereospermum tetragonum DC and isolation of active principles
Kumar et al. Antioxidant, Antinociceptive and Anti-inflammatory activities of Rhynchosia minima (L) DC
JP4157767B2 (ja) 退行性脳神経系疾患の予防および治療効果を有するハンゲショウ抽出物
KR101055920B1 (ko) 탱자로부터 분리한 8-메톡시소랄렌을 포함하는 알츠하이머 병 예방 또는 치료용 조성물 및 상기 화합물의 분리방법
KR100697235B1 (ko) 관동화 추출물 또는 투실라곤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
Ali et al. Anti-Atherosclerosis and Anti-Hypertensive Effects of Flavonoid Isorhamnetin Isolated from the Bark of Cordia dichotoma L
Korkotian et al. Flavonoids Antagonize Effects of Alcohol in Cultured Hippocampal Neurons: A Drug Discovery Study
KR20040063200A (ko) 아실 코에이:디아실글리세롤 아실트랜스퍼라제 저해활성을 갖는 고삼 추출물 또는 프레닐플라보노이드화합물을 함유하는 조성물
KR100703596B1 (ko) 연수추출물 또는 그로부터 분리한캠프페롤-3-글루쿠로나이드를 함유하는 고지혈증의 예방 및치료용 조성물
KR100615357B1 (ko) 인지력 향상효과를 갖는 신규 알칼로이드 유도체 화합물및 이를 함유하는 조성물
WO2026104861A1 (en) Iodbr1 and derivatives thereof for treating sleep disorders
SACHAN et al. Evaluation Of Analgesic Activity Of Jasminum Grandiflorum Linn Leaf Extracts
BRPI0804525A2 (pt) processo de obtenção de um extrato padronizado, extrato obtido, composição farmacêutica, método de tratamento e uso de dito extrato
Jain et al. A TIARTHRITIC ADA TIPYRETIC ACTIVITY OF MITRAGY A PARVIFOLIA LEAVES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.